Cells Cor.At® ES derived Cardiomyocytes
Species Mouse /Strain 129S2/SvPas)
Reporter Gene Choice
Purity 100% Pure Cardiomyocytes
Service content Analysis of effects of test compounds on field action potentials and other electrophysiological properties of human iPS derived Cor.4U cardiomyocytes using MEA analysis.
Timeline Experiment time: 2 weeks per compound.
Draft report: within 4 weeks
  order
Product Title
 

Create PDF Recommend Print

Murine Cor.At®-based Mel.Cor® assay service

Mel.Cor®  is an in vitro assay that utilizes Axiogenesis Cor.At® cardiomyocytes to reproduce an authentic cardiac cellular environment for drug pharmacology screening. Mel.Cor®  has important natural features that are lacking in current electrophysiological in vitro assay methods and is capable to display hERG effects.

Mel.Cor® is a physiologically authentic system that integrates a full range of cellular mechanisms which regulate cardiac potentials, such as the interaction between ion channel subunits (Na+ ,Ca2+ ,K+ ). Mel.Cor® also permits the simultaneous detection of drug effects on all ion channels, as well as on beta-adrenergic and muscarinic receptors. Other current systems for in vitro electrophysiological analysis do not provide this physiologically accurate cardiac cellular environment so the data they produce is of limited value. Mel.Cor® is also highly efficient and economical and thus can be particularly beneficial in screening large compound libraries.

Advantages Cor.At MelCor
  • standardized, primary-like, and pure cardiomyocytes.
  • assessment of the potential to delay cardiac repolarization.
  • predictive for pharmcology preclinical safety pharmacology.
  • non-invasive test system.
  • Low amount of compound required.
  • cost effective.